JP2019536803A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536803A5 JP2019536803A5 JP2019529914A JP2019529914A JP2019536803A5 JP 2019536803 A5 JP2019536803 A5 JP 2019536803A5 JP 2019529914 A JP2019529914 A JP 2019529914A JP 2019529914 A JP2019529914 A JP 2019529914A JP 2019536803 A5 JP2019536803 A5 JP 2019536803A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- delay
- composition according
- reduce
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 23
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 9
- 108091034117 Oligonucleotide Proteins 0.000 claims 7
- 239000002777 nucleoside Substances 0.000 claims 7
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 6
- 230000024924 glomerular filtration Effects 0.000 claims 5
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 4
- 239000002464 receptor antagonist Substances 0.000 claims 4
- 229940044551 receptor antagonist Drugs 0.000 claims 4
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims 3
- 206010001580 Albuminuria Diseases 0.000 claims 3
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 3
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 3
- 206010038490 Renal pain Diseases 0.000 claims 3
- 238000011374 additional therapy Methods 0.000 claims 3
- 229940109239 creatinine Drugs 0.000 claims 3
- 229940104302 cytosine Drugs 0.000 claims 3
- 230000006866 deterioration Effects 0.000 claims 3
- 208000006750 hematuria Diseases 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 208000030761 polycystic kidney disease Diseases 0.000 claims 3
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims 2
- 102000005862 Angiotensin II Human genes 0.000 claims 2
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 2
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 2
- 101800000733 Angiotensin-2 Proteins 0.000 claims 2
- 206010011732 Cyst Diseases 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
- 102000004136 Vasopressin Receptors Human genes 0.000 claims 2
- 108090000643 Vasopressin Receptors Proteins 0.000 claims 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 claims 2
- 229950006323 angiotensin ii Drugs 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 208000031513 cyst Diseases 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 230000005713 exacerbation Effects 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 239000003668 hormone analog Substances 0.000 claims 2
- 230000003907 kidney function Effects 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 239000003087 receptor blocking agent Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 208000010061 Autosomal Dominant Polycystic Kidney Diseases 0.000 claims 1
- 208000002814 Autosomal Recessive Polycystic Kidney Diseases 0.000 claims 1
- 208000017354 Autosomal recessive polycystic kidney disease Diseases 0.000 claims 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 102400000739 Corticotropin Human genes 0.000 claims 1
- 101800000414 Corticotropin Proteins 0.000 claims 1
- 229940097420 Diuretic Drugs 0.000 claims 1
- 108010061435 Enalapril Proteins 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 102000013382 Gelatinases Human genes 0.000 claims 1
- 108010026132 Gelatinases Proteins 0.000 claims 1
- 102100034459 Hepatitis A virus cellular receptor 1 Human genes 0.000 claims 1
- 101710185991 Hepatitis A virus cellular receptor 1 homolog Proteins 0.000 claims 1
- 101100029888 Homo sapiens PKD1 gene Proteins 0.000 claims 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 claims 1
- 102000019298 Lipocalin Human genes 0.000 claims 1
- 108050006654 Lipocalin Proteins 0.000 claims 1
- 108010007859 Lisinopril Proteins 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- 101150056230 PKD1 gene Proteins 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 208000022185 autosomal dominant polycystic kidney disease Diseases 0.000 claims 1
- -1 balsartan Chemical compound 0.000 claims 1
- 229960004530 benazepril Drugs 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical group C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 claims 1
- 229960003736 bosutinib Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 229960000830 captopril Drugs 0.000 claims 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical group SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims 1
- 229960000258 corticotropin Drugs 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229960000873 enalapril Drugs 0.000 claims 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims 1
- 208000028208 end stage renal disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 229960002394 lisinopril Drugs 0.000 claims 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- 229940124302 mTOR inhibitor Drugs 0.000 claims 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 1
- 210000000440 neutrophil Anatomy 0.000 claims 1
- 125000003835 nucleoside group Chemical group 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 101150112863 pkd2 gene Proteins 0.000 claims 1
- 229960001455 quinapril Drugs 0.000 claims 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims 1
- 229960003401 ramipril Drugs 0.000 claims 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 239000002461 renin inhibitor Substances 0.000 claims 1
- 229940086526 renin-inhibitors Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- 230000002099 somatostatinotropic effect Effects 0.000 claims 1
- 229960002256 spironolactone Drugs 0.000 claims 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- GYHCTFXIZSNGJT-UHFFFAOYSA-N tolvaptan Chemical group CC1=CC=CC=C1C(=O)NC(C=C1C)=CC=C1C(=O)N1C2=CC=C(Cl)C=C2C(O)CCC1 GYHCTFXIZSNGJT-UHFFFAOYSA-N 0.000 claims 1
- 229960001256 tolvaptan Drugs 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662430164P | 2016-12-05 | 2016-12-05 | |
| US62/430,164 | 2016-12-05 | ||
| PCT/US2017/064432 WO2018106568A1 (en) | 2016-12-05 | 2017-12-04 | Methods for treatment of polycystic kidney disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019536803A JP2019536803A (ja) | 2019-12-19 |
| JP2019536803A5 true JP2019536803A5 (enExample) | 2020-11-12 |
| JP7105775B2 JP7105775B2 (ja) | 2022-07-25 |
Family
ID=61074503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529914A Active JP7105775B2 (ja) | 2016-12-05 | 2017-12-04 | 多発性嚢胞腎疾患の処置のための方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US20190345494A1 (enExample) |
| EP (1) | EP3548011B1 (enExample) |
| JP (1) | JP7105775B2 (enExample) |
| KR (2) | KR20240148005A (enExample) |
| CN (1) | CN110225747B (enExample) |
| AU (1) | AU2017372695B2 (enExample) |
| CA (1) | CA3045461A1 (enExample) |
| CL (1) | CL2019001526A1 (enExample) |
| EA (1) | EA201991370A1 (enExample) |
| IL (1) | IL266989B2 (enExample) |
| MA (1) | MA46970A (enExample) |
| MX (1) | MX2019006337A (enExample) |
| MY (1) | MY202466A (enExample) |
| NZ (2) | NZ753811A (enExample) |
| WO (1) | WO2018106568A1 (enExample) |
| ZA (1) | ZA201903608B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016312590B2 (en) | 2015-08-26 | 2021-12-02 | Board Of Regents Of The University Of Texas System | Methods for treatment of polycystic kidney disease |
| WO2020038968A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
| AU2022361062A1 (en) | 2021-10-08 | 2024-03-21 | Regulus Therapeutics Inc. | Methods and compositions for treatment of polycystic kidney disease |
| TW202539703A (zh) * | 2024-03-11 | 2025-10-16 | 美商雷格勒斯治療公司 | 治療多囊性腎病之方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5417201A (en) * | 1996-05-24 | 2001-09-20 | Genzyme Corporation | Polycystic kidney disease gene |
| CN101056991A (zh) | 2004-04-20 | 2007-10-17 | 基因耐克生物医学制品有限公司 | 检测ncRNA的方法 |
| GB0523659D0 (en) * | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| WO2008042973A2 (en) | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
| EP2714904B1 (en) | 2007-06-14 | 2017-04-12 | Mirx Therapeutics ApS | Oligonucleotides for modulation of target rna activity |
| ES2463665T3 (es) * | 2007-10-04 | 2014-05-28 | Stella Aps | Tratamiento de combinación para el tratamiento de infección por virus de la hepatitis C |
| EP2268811A1 (en) * | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| KR20120107088A (ko) | 2009-11-11 | 2012-09-28 | 샌포드-번햄 메디칼 리서치 인스티튜트 | ⅰＰＳ 세포들의 생산 및 조절 방법 및 그들의 조성물들 |
| US20150283147A1 (en) * | 2012-10-19 | 2015-10-08 | Synta Pharmaceuticals Corp. | Treating polycystic kidney disease with hsp90 inhibitory compounds |
| EP3105327A4 (en) * | 2014-02-12 | 2017-10-18 | Thomas Jefferson University | Compositions and methods of using microrna inhibitors |
| AU2016312590B2 (en) | 2015-08-26 | 2021-12-02 | Board Of Regents Of The University Of Texas System | Methods for treatment of polycystic kidney disease |
| US11157828B2 (en) | 2016-12-08 | 2021-10-26 | Microsoft Technology Licensing, Llc | Tomography and generative data modeling via quantum boltzmann training |
-
2017
- 2017-12-04 CA CA3045461A patent/CA3045461A1/en active Pending
- 2017-12-04 NZ NZ753811A patent/NZ753811A/en unknown
- 2017-12-04 KR KR1020247032150A patent/KR20240148005A/ko active Pending
- 2017-12-04 CN CN201780083381.6A patent/CN110225747B/zh active Active
- 2017-12-04 JP JP2019529914A patent/JP7105775B2/ja active Active
- 2017-12-04 MX MX2019006337A patent/MX2019006337A/es unknown
- 2017-12-04 US US16/466,752 patent/US20190345494A1/en not_active Abandoned
- 2017-12-04 NZ NZ794203A patent/NZ794203A/en unknown
- 2017-12-04 MY MYPI2019003144A patent/MY202466A/en unknown
- 2017-12-04 EP EP17835968.3A patent/EP3548011B1/en active Active
- 2017-12-04 AU AU2017372695A patent/AU2017372695B2/en active Active
- 2017-12-04 KR KR1020197019107A patent/KR102780365B1/ko active Active
- 2017-12-04 IL IL266989A patent/IL266989B2/en unknown
- 2017-12-04 EA EA201991370A patent/EA201991370A1/ru unknown
- 2017-12-04 WO PCT/US2017/064432 patent/WO2018106568A1/en not_active Ceased
- 2017-12-04 MA MA046970A patent/MA46970A/fr unknown
-
2019
- 2019-06-05 ZA ZA2019/03608A patent/ZA201903608B/en unknown
- 2019-06-05 CL CL2019001526A patent/CL2019001526A1/es unknown
-
2020
- 2020-08-27 US US17/004,975 patent/US20200392501A1/en not_active Abandoned
-
2022
- 2022-03-21 US US17/700,339 patent/US20220213483A1/en not_active Abandoned
-
2023
- 2023-11-30 US US18/524,302 patent/US20240141350A1/en not_active Abandoned
-
2025
- 2025-04-07 US US19/172,583 patent/US20260055406A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528945A5 (enExample) | ||
| JP2015536301A5 (enExample) | ||
| RU2018108206A (ru) | Способы лечения поликистозной болезни почек | |
| CA2780034C (en) | Benzimidazole-imidazole derivatives | |
| RU2002129569A (ru) | Новое медицинское применение ингибиторов альдостеронсинтазы индивидуально или в сочетании с антагонистами ат1-рецептора | |
| US20150297598A1 (en) | Methods for treating renal disease | |
| TNSN07312A1 (en) | Combination of organic compounds | |
| JP2018507244A5 (enExample) | ||
| WO2011156757A1 (en) | Combination of anti-hcv compounds with ribavirin for the treatment of hcv | |
| RU2020113612A (ru) | Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2 | |
| WO2004075852A2 (en) | Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions | |
| KR20100130596A (ko) | 부신 피질 자극 호르몬 방출 인자 길항 작용을 갖는 3 환식 화합물 및 이를 함유하는 약학 조성물 | |
| US20060286105A1 (en) | Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency | |
| Roberts et al. | Adenosine receptor expression in the development of renal fibrosis following ischemic injury | |
| US20180263979A1 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
| Makówka et al. | A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients–a pilot open label study | |
| Pereira et al. | A novel Ca²+ channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension | |
| JP2005501815A (ja) | 治療方法 | |
| CA2557976A1 (en) | Use of antagonists of the cb1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases | |
| JP2020518633A5 (enExample) | ||
| CA2581787A1 (en) | Use of tgf-b antagonists to limit nephrotoxicity of immunosuppressive agents | |
| TH1901003360A (th) | โอลิโกนิวคลีโอไทด์สำหรับใช้ในการบำบัดโรคถุงน้ำในไต | |
| Gola et al. | A new form of amphotericin B–the complex with copper (II) ions–downregulates sTNFR1 shedding and changes the activity of genes involved in TNF-induced pathways: AmB–Cu2+ downregulates sTNFR1 shedding and changes the activity of genes involved in TNF-induced pathways | |
| De Witt et al. | L-163,491 is a partial angiotensin AT1 receptor agonist in the hindquarters vascular bed of the cat | |
| US20130172383A1 (en) | Treatment of fibrosing disorders |